Advair: A Big Generic Opportunity And A Big Question Mark In 2017
Executive Summary
Takeda’s Velcade, Pfizer’s Viagra and Gilead’s Viread are among the brand drugs expected to face generic competition in the US for the first time in 2017. One unknown is if FDA will approve Mylan’s or Hikma’s ANDAs for a generic version of GSK’s Advair.
You may also be interested in...
Mylan Plans Summer Launch For Advair Generic, Now Called Wixela Inhub
Wixela Inhub could be the first interchangeable generic version of the blockbuster asthma drug on the US market if it is approved by FDA.
Mylan Plans Summer Launch For Advair Generic, Now Called Wixela Inhub
Wixela Inhub could be the first interchangeable generic version of the blockbuster asthma drug on the US market if it is approved by FDA.
GSK Braces For Impact: Advair Generic Could Reduce US Brand To £1Bn
Although it’s not yet clear if an interchangeable version of the respiratory blockbuster will be approved by FDA, CEO Andrew Witty prepared investors to expect a hit, forecasting that a mid-year launch could significantly reduce revenues.